Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
SYREthis companySpyre Therapeutics, Inc.	$109.22	-16.55×	2.93×	0×	-9.6×	-98.7%	0.0%	0.0%	0.0%	-21.7%	-29.1%	-8.1%	0×	0.41×	0×	13.25×	0.0%	2	73.63	1	D+
ACRSAclaris Therapeutics, Inc.	$4.22	-5.68×	3.58×	47.18×	-5.45×	-122.2%	73.3%	-975.9%	-829.6%	-63.0%	-57.7%	-12.8%	0.02×	0.28×	0×	5.28×	0.0%	2	-2.65	1	D+
ANABAnaptysBio, Inc.	$47.82	-70.26×	24.14×	3.83×	9.73×	-639.3%	99.0%	20.4%	-5.6%	-35.6%	14.6%	2.2%	0.38×	-3.24×	0.6×	9.07×	0.0%	5	2.21	3	B
ARDXArdelyx, Inc.	$2.90	-22.42×	8.42×	3.45×	-53.09×	-5941.7%	89.5%	-10.1%	-15.1%	-36.9%	-9.9%	-3.1%	1.27×	-4.92×	-1.44×	4.31×	0.0%	2	-0.11	1	D+
IMUXImmunic, Inc.	$8.02	-0.86×	-12.46×	0×	-0.7×	-91.8%	0.0%	0.0%	0.0%	1456.2%	1693.4%	-103.4%	-0.1×	0.15×	0×	0.75×	0.0%	2	-5.39	2	C
ODTXOdyssey Therapeutics, Inc.	$19.19	-3.05×	-0.93×	152.07×	-3.03×	-100.4%	100.0%	-5415.2%	-4994.9%	30.4%	-64.4%	-28.9%	-0.06×	0.1×	-9,479.76×	7.2×	0.0%	—	—	2	C+
Peer median	—	-5.68×	3.58×	3.83×	-3.03×	-122.2%	89.5%	-10.1%	-15.1%	-35.6%	-9.9%	-12.8%	0.02×	0.1×	0×	5.28×	0.0%	2	-1.38	2	—